Drug Channels

JULY 5, 2022

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. This event is part of The Drug Channels 2022 Video Webinar Series. to 1:30 p.m.

Drug Pricing 83

Drug Pricing 83

Drug Channels

DECEMBER 5, 2023

The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers. Below, I walk through the economic fundamentals to help you understand another obscure aspect of our opaque drug pricing system. to 1:30 p.m.

Drug Pricing 81

Drug Pricing Hospitals 81

Drug Channels

MARCH 31, 2023

This week, I’m rerunning some popular posts while I prepare for today’s live video webinar: Discount Cards, Cost-Plus Pharmacies, and PBMs: Trends, Controversies, and Outlook. Time for the Drug Channels annual reality check on drug pricing. d/b/a Drug Channels Institute. healthcare expenditures.

Drug Pricing 73

Drug Pricing 73

Drug Channels

SEPTEMBER 8, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest video webinar: Drug Channels Update: Buy-and-Bill Market Trends. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Friday, September 24, 2021, from 12:00 p.m.

Drug Pricing 72

Drug Pricing Biosimilars Hospitals 72

Drug Channels

NOVEMBER 15, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for a new live video webinar: Drug Channels Outlook 2022. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. The Outlook 2022 marks our third annual outlook webinar.

Specialty Pharmacies 66

Specialty Pharmacies Drug Pricing Biosimilars 66

Big Molecule Watch

JULY 18, 2023

On June 30, 2023, the Centers for Medicare & Medicaid Services (CMS) released its updated final program guidance covering the Inflation Reduction Act’s Medicare Drug Price Negotiation Program for the first round of negotiations, which will occur during 2023 and 2024 and result in prices that will be effective beginning in 2026.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 21, 2024

How will the most consequential change in federal drug pricing policy affect drug pricing? Find out during Drug Channel Implications of the Inflation Reduction Act , a new live video webinar with Adam J. Click here to learn more and reserve your spot at the April 5 webinar.

Drug Pricing 97

Drug Pricing 97

Drug Channels

JUNE 1, 2021

Fein, CEO of Drug Channels Institute (DCI) and the author of Drug Channels , invites you to join him for his latest live video webinar: Drug Channels Update: 340B Controversies and Outlook. This event is part of The Drug Channels 2021 Quarterly Video Webinar Series. Friday, June 25, 2021 (12:00 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

JUNE 22, 2022

See The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards. In the video below, I discuss how generic drug pricing and the rise of patient-paid, discount card prescriptions pose a risk to pharmacy benefit plans and the PBM business. d/b/a Drug Channels Institute.

Drug Pricing 74

Drug Pricing 74

Drug Channels

MARCH 23, 2021

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. It was another year of unexpected drug price developments. In 2020, brand-name drug net prices dropped for the third consecutive year.

Drug Pricing 52

Drug Pricing 52

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 130

Biosimilars Drug Pricing Compounding Drug Development 130

Drug Channels

AUGUST 21, 2020

As regular readers know, I believe the 340B Drug Pricing Program needs to evolve into a more transparent, properly regulated program. To help the industry learn more about 340B rebates, Kalderos is sponsoring a live video webinar: Evolving 340B: Moving from Discounts to Rebates. to 1:00 p.m.

Drug Pricing 52

Drug Pricing 52

Drug Channels

MARCH 25, 2021

This week, I’m rerunning some popular posts while I prepare for tomorrow's live video webinar: Drug Channels Quarterly Update: Patients, Payers, and PBMs. When Americans complain about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed.

Drug Pricing 52

Drug Pricing 52

Drug Channels

DECEMBER 8, 2020

When Americans complains about “drug prices,” most are actually complaining about the share of costs they pay—and how those costs are computed. drug channel. Today, I review four crucial issues that the new Congress could tackle to address affordability, patients' out-of-pocket obligations, and prescription prices.

Drug Pricing 52

Drug Pricing 52

Safe Biologics

FEBRUARY 1, 2024

In January, the Generics and Biosimilars Initiative (GaBI) published a whitepaper entitled “ Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines” The paper’s content is drawn from a webinar on the same topic hosted by ASBM and GaBI on July 26, 2023.

Drug Pricing 100

Drug Pricing Biosimilars 100

Drug Channels

MARCH 12, 2024

Next week, Drug Channels Institute (DCI) will release our 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 7, 2024. Pharmacies and Pharmacy Benefit Managers. For 2023, DCI estimates that U.S. to 1:30 p.m.

Drug Pricing 79

Drug Pricing 79

Safe Biologics

JUNE 12, 2023

Coming Soon: ASBM/GaBI Webinar on IRA’s Medicare Price Negotiation Provisions ASBM and the Generics and Biosimilars Initiative (GaBI) are in the final planning stages for the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA).

Biosimilars 100

Biosimilars Drug Pricing Compounding Drug Development 100

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Safe Biologics

JULY 20, 2023

REGISTER NOW: July 26th ASBM/GaBI Webinar on IRA Medicare Price Negotiation On July 26th, ASBM and the Generics and Biosimilars Initiative (GaBI) will host the first of two webinars examining the implications for patients and healthcare providers of the recently-passed Inflation Reduction Act (IRA). REGISTER HERE. Read it here.

Biosimilars 130

Biosimilars Drug Pricing Drug Development 130

Drug Channels

OCTOBER 12, 2020

Informa Connect-CBI’s 6th Edition Drug Pricing Transparency Congress. November 16-17, 2020 | Virtual Event www.informaconnect.com/drug-pricing-transparency. Drug Channels Readers: View the complete agenda and register today. Be sure to use your exclusive promo DRUG30 to save $300 *.

Drug Pricing 40

Drug Pricing 40

Drug Channels

APRIL 1, 2024

This week, I’m rerunning some popular posts while I prepare for Friday’s live video webinar: Drug Channel Implications of the Inflation Reduction Act. The common factor behind these two disparate situations: Pharmaceutical wholesalers’ unusual pricing for brand-name drugs sold to pharmacies, hospitals, and other buyers.

Drug Pricing 85

Drug Pricing Hospitals 85

Big Molecule Watch

SEPTEMBER 14, 2023

Two weeks ago, HHS announced the first 10 drugs that will be subject to the new Drug Price Negotiation Program under the Inflation Reduction Act (“IRA”). Six of the manufacturers whose drugs are on the list and several other interested groups have filed lawsuits challenging the Program.

Drug Pricing 67

Drug Pricing Drug Development 67

Big Molecule Watch

OCTOBER 2, 2023

Ohio, Judge Newman) issued the first substantive order addressing legal challenges to the Drug Price Negotiation Program of the Inflation Reduction Act. New Complaint by Novo Nordisk Also on Friday, Novo filed a new Complaint challenging the Drug Price Negotiation Program and CMS’s actions in implementing it.

Drug Pricing 62

Drug Pricing Documentation 62

Drug Channels

DECEMBER 15, 2023

This week, I’m rerunning some popular posts while I prepare for today’s Drug Channels Outlook 2024 live video webinar. Drug Channels has just obtained new details on the size of the 340B Drug Pricing Program. The difference between list prices and discounted 340B purchases also grew, to $52.3 billion (+$2.6

Drug Pricing 79

Drug Pricing Hospitals 79

Drug Channels

SEPTEMBER 29, 2023

According to Kalderos, at least 5% of commercial rebates are paid for prescriptions that also have discounts under the 340B Drug Pricing Program. To learn about Kalderos’ Commercial Discount Monitoring solution, close your eyes and slip away with Micah at his free webinar on November 1, 2023, at 2:00 p.m.

Drug Pricing 79

Drug Pricing 79

Drug Channels

JULY 28, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. That’s why I refer to them as drug pricing flat earthers (#DPFE).

Drug Pricing 87

Drug Pricing Pharmaceutical Manufacturing 87

Safe Biologics

DECEMBER 3, 2023

ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars. Learn more about ACR Convergence 2023 here.

Biosimilars 130

Biosimilars Labelling Drug Pricing Packaging 130

Drug Channels

MARCH 7, 2024

On March 19, 2024, Drug Channels Institute will release The 2024 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. prescription drug channels. Email Paula Fein ( paula@drugchannels.net ) if you’d like to bundle the report purchase with access to DCI’s video webinars.

Drug Pricing 76

Drug Pricing 76

Drug Channels

JUNE 13, 2023

When rebates and discounts were factored in, brand-name drug prices again declined—or grew slowly—in 2022. However, some companies had net price gains. Consistent with our previous analyses, rebates and discounts reduced the selling prices of brand-name drugs at the biggest drugmakers to less than half of their list prices.

Drug Pricing 78

Drug Pricing Pharmaceutical Manufacturing 78

Drug Channels

JUNE 20, 2023

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: PBMs and the Battle Over Patient Support Funds: Accumulators, Maximizers, and Alternative Funding. Last Friday was the last day to submit comments on CMS's initial guidance on the drug price negotiation program.

Drug Pricing 82

Drug Pricing 82

Drug Channels

MARCH 19, 2024

drug pricing, reimbursement, and dispensing system. Email Paula Fein ( paula@drugchannels.net ) if you’d like to bundle your report purchase with access to DCI’s video webinars. The 2024 Economic Report on U.S. This 2024 edition includes substantial new material—outlined on page ix of the report overview.

Drug Pricing 70

Drug Pricing 70

Drug Channels

NOVEMBER 28, 2023

In this issue: A reality check on Express Scripts’ purported “cost-based” pharmacy network Mark Cuban explains how and why the PBM market will change Why two drug prices are better than one Pharmacists sing the retail pharmacy shakeout blues Plus, two Philly legends meet at a cardiology conference! d/b/a Drug Channels Institute.

Drug Pricing 74

Drug Pricing 74

Safe Biologics

NOVEMBER 12, 2023

View the full webinar here or watch individual segments linked below. Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. Thanks to the IRA’s price controls, medical marvels like Keytruda will now be even more difficult to achieve.

Biosimilars 130

Biosimilars Drug Pricing Packaging Labelling 130

Drug Channels

JULY 26, 2022

This week, I’m rerunning some popular posts while I prepare for this Friday’s live video webinar: Specialty Drugs Update: Trends, Controversies, and Outlook. More than $122 billion in "savings" (offsets) from the current drug pricing reconciliation legislation comes from blocking rebate reform—which never even happened.

Drug Pricing 66

Drug Pricing 66

Drug Channels

JULY 12, 2022

Despite what you may have heard, pharmacy participation in the 340B Drug Pricing Program continues to thrive. Drug Channels Institute’s latest analysis reveals that an astonishing 32,000 pharmacy locations —more than half of the entire U.S. d/b/a Drug Channels Institute. Read on for details and my commentary below.

Drug Pricing 84

Drug Pricing Hospitals 84

Drug Channels

MARCH 8, 2023

Next week, Drug Channels Institute will release our 2023 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. We’re offering special discounted pricing if you order before April 3, 2023. How will GoodRx and Mark Cuban Cost Plus Drug Company affect the pharmacy industry? to 1:30 p.m.

Specialty Pharmacies 85

Specialty Pharmacies Drug Pricing 85

Drug Channels

APRIL 16, 2021

Jeff discusses aspects of our drug pricing system that lead to decreased new and refill prescription volume, higher out-of-pocket costs for patients, and therapy abandonment. Read on for Jeff’s insights.

Drug Pricing 52

Drug Pricing 52